Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.

Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.

Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.

Abstract: Method for detecting nucleic acids which employs a double-stranded oligonucleotide probe containing i) a first probe including a first label moiety, and ii) a second probe partially complementary with the first probe and including a second label moiety capable of interacting with the first moiety when brought in close proximity with each other, the second moiety being a quencher or acceptor of emission of the first moiety. The first or second probe includes a sequence complementary to that of a target nucleotide, and the second or first probe, respectively, includes a sequence complementary to a complement of the target nucleotide sequence of the nucleic acid to be detected. Oligonucleotides for determining Chlamydia trachomatis are also disclosed.

Abstract: Method for detecting nucleic acids which employs a double-stranded oligonucleotide probe containing i) a first probe including a first label moiety, and ii) a second probe partially complementary with the first probe and including a second label moiety capable of interacting with the first moiety when brought in close proximity with each other, the second moiety being a quencher or acceptor of emission of the first moiety. The first or second probe includes a sequence complementary to that of a target nucleotide, and the second or first probe, respectively, includes a sequence complementary to a complement of the target nucleotide sequence of the nucleic acid to be detected. Oligonucleotides for determining Chlamydia trachomatis are also disclosed.

Abstract: A reagent container having an inner surface upon which at least two reagents are dried, with the first reagent dried on a first area separate from a second area where the second reagent is dried. The first and second reagents are a nucleic acid polymerase and its substrate. A method is disclosed which includes dispensing at least the first and second reagents onto separate areas of the inner surface of the reagent container, and removing excess water from the reagents. The reagent container can be used in a polymerase chain reaction (PCR) assay, an assay that utilizes a reverse transcriptase, a reverse transcriptase polymerase chain reaction, an immuno-PCR assay, a nucleic acid sequence based assay, a proximity ligation assay, a ligase chain reaction assay, a rolling circle amplification assay, and a strand displacement amplification assay.

Abstract: This invention concerns an antibody which binds with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA. This invention further concerns an immunoassay and a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and/or healthy male subjects without PCa, patients with aggressive PCa from patients with indolent PCa and/or patients with clinically localized and/or organ confined PCa from patients with extraprostatic extension of PCa and/or PCa with metastatic spread to lymph nodes or bone marrow using said antibody.

Abstract: A method for rapid thermal control of a reaction volume from a preceding temperature to a target temperature includes first bringing at least the reaction vessel's second wall, which has high thermal conductivity, into direct contact with a first thermal block at a temperature higher than the target temperature if the target temperature is higher than the preceding temperature, or at a temperature lower than the target temperature if the target temperature is lower than the preceding temperature, until the reaction volume temperature is at least close to the target temperature; and then bringing the second wall into direct contact with a second thermal block at the target temperature. Also disclosed is a system (20) for detecting and/or quantitating a biological and/or chemical analyte in a sample and a software product for the system.

Abstract: A homogeneous bioassay including a first group labelled with an energy donor and a second group labelled with an energy acceptor, where the donor is a luminescent lanthanide label capable of up-converting a lower-energy excitation to a higher-energy emission, where the acceptor is either a luminescent or a non-luminescent label, and where the increase or decrease, respectively, in energy transfer from the donor to the acceptor resulting from shortening or lengthening of the distance between the labels is measured. The assay is performed in a biological fluid which absorbs radiation in the wavelength range 300 to 600 nm, the measurement is carried out at a wavelength >570 nm, and the donor label, which is excitable at wavelength longer than its emission wavelength, is excited in the wavelength window in which the biological fluid does not essentially absorb the excitation radiation.

Abstract: The invention relates to a method for rapid thermal control of a reaction volume (4) of a reaction vessel (2) for a change of temperature of the reaction volume (4) from a preceding temperature to a target temperature.

Abstract: This invention relates to a reagent container for detection and/or quantitation of at least one biological or chemical analyte from a sample, said reagent container comprising an inner surface enclosing a volume, wherein volume analytical reactions of at least one analysis for detection and/or quantitation of at least one analyte take place, and at least two reagents of an analysis of an analyte have been dried onto said inner surface and at least a first said reagent has been dried onto a first area of the inner surface distinctly separate, i.e. without any overlap, from a second area of the inner surface onto which at least a second said reagent has been dried. Characteristic for the reagent container is that the first reagent and the second reagent form a pair wherein the first reagent is an enzyme and the second reagent is a substrate of said enzyme, and said pair consists of a nucleic acid polymerase and substrate thereof.

Abstract: This invention concerns a luminescence energy transfer based homogeneous bioassay comprising a first group labelled with an energy donor and a second group labelled with an energy acceptor, wherein the donor is a luminescent lanthanide label, said label being able to up-convert a lower-energy excitation to a higher-energy emission, the acceptor is either a luminescent or a non-luminescent label, and the increase or decrease, respectively, in energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between said labels is measured. According to the invention, the assay is performed in a biological fluid which absorbs radiation in the wavelength range 300 to 600 nm, the measurement is carried out at a wavelength>570 nm, and the donor label, which is excitable at wavelength longer than its emission wavelength, is excited in the wavelength window in which the biological fluid does not essentially absorb the excitation radiation.

Abstract: This invention concerns a method for the assessment of bone fragility and fracture risk, or osteoporosis, in a person. In said method, the concentration of gamma-carboxylated osteocalcin (COC) and optionally also the concentration of intact or total osteocalcin (IOC or TOC, respectively) in a body fluid sample of said person is measured. The concentration of gamma-carboxylated osteocalcin (COC) so obtained is compared to the mean concentration of gamma-carboxylated osteocalcin (mean COC) in similar body fluid samples of the population of the same age and sex. Alternatively, the determined ratio COC/IOC or COC/TOC for said person, is compared to the mean ratio COC/IOC or COC/TOC, (mean ratio COC/IOC or mean ratio COC/TOC) determined from measurements in similar body fluid samples of the population of the same age and sex. A measured COC that is lower than the mean COC is used as indication of osteoporosis, bone fragility or increased risk of bone fracture in said person.

Abstract: The invention relates to an isolated osteocalcin fragment derived from human urine, said fragment being characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence 1                     6   7 Tyr-Leu-Tyr-Gln-Trp-Leu-Gly-Ala-Pro-Val-Pro-Tyr-                 17              21          24 Pro-Asp-Pro-Leu-Glu-Pro-Arg-Arg-Glu-Val-Cys-Glu-                   30 Leu-Asn-Pro-Asp-Cys-Asp-Glu-Leu-Ala-Asp-His-Ile- Gly-Phe-Gln-Glu-Ala-Tyr-Arg-Arg-Phe-Tyr-Gly-Pro- Val

Abstract: This invention concerns an antibody wherein said antibody does bind with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody, obtainable through immunization with an uncleaved form of PSA and selected by its differential reactivity with the intact and internally cleaved forms, does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA.

Abstract: Method for a homogeneous biospecific affinity assay for determining the content of a substance (analyte) in a biological sample. The assay is carried out in an aqueous reaction medium by means of time-resolved fluorescence spectroscopy and with a biospecific affinity reactant labeled with a lanthanide chelate in which a lanthanide ion exhibiting ionic fluorescence is chelated by a ligand bound covalently to the reactant. The characteristic feature is(i) that the lanthanide chelate formed by the lanthanide ion together with the covalently bound ligand forms a fluorescent chelate, and(ii) that a modulator is added which stabilizes the lanthanide chelate so that the lanthanide fluorescence as measured from the medium becomes a practically pure function of the analyte concentration therein.

Abstract: A method for the detection of a nucleotide sequence of a nucleic acid in a sample. The method comprises the steps: (i) contacting under hybridization condition the single stranded form of the nucleotide sequence with a single stranded nucleic acid probe, in which plurality of rare earth metal chelate groups is covalently linked via a water-soluble polymer of non-nucleic acid structure to a nucleotide acid that as one of its strand has the nucleotide sequence to be detected and as the other strand the nucleotide sequence of the probe, and (ii) detecting the formation of double stranded nucleic acid. The plurality of rare earth metal chelate groups have at least one metal ion selected from the group consisting of Eu.sup.3+, Sm.sup.3+, Tb.sup.3+ and Dy.sup.3+ as the chelated rare earth metal. The probes as given above are also claimed.

Abstract: The method for demonstrating the presence of an activity of an enzyme by(a) incubating said enzyme with a fluorogenic substrate A which is converted by the enzyme to a product B differing from A in respect to its fluorescent properties, A and/or B carrying a chromophore which is a triplet sensitizer having a triplet energy level above the excitation energy level of a lanthanide ion selected from the group consisting of Eu.sup.3+, Tb.sup.3+, Dy.sup.3+ and Sm.sup.3+ and which is capable of chelating said lanthanide ion by means of an oxygen or nitrogen atom in said chromophore, and that B differs from A either by(i) carrying a different chromophore, or(ii) having a different chelating ability, and(b) measuring the change in fluorescence caused by said enzyme.

Abstract: Method for quantitative determination of a biospecific affinity reaction in which an immunochemical compound labelled with a lanthanide chelate is used which can be detected by means of time-resolved fluorescence in which the amount of labelled compound present in the biospecific affinity reaction can be measured without the separation of free and biospecifically bound labelled compound having to be carried out.

Abstract: A method for determining NADH and/or NADPH-concentrations, for instance in NADH- or NADPH transforming systems, the method comprising the step of bringing the sample subject to determination in contact with the bioluminescent reagent based on bacteria luciferase, NAD(P)H-FMN oxidoreductase, FMN and aliphatic aldehyde, whereby a reaction takes place, where NAD(P)H is oxidized and FMN is reduced, the reaction being catalyzed by the oxidoreductase, whereafter the FMNH.sub.